Product Catalog


> Recombinant Protein > CHO Cell Expressed > Interferon beta / IFN-beta / IFNB Protein (Native) Interferon beta / IFN-beta / IFNB Protein (Native)
| Catalog | Size (Price) | Quantity | In Stock | Operation | Other Information |
| 10704-HNAC |
|
YES |
|
![]() |
|
Interferon beta / IFN-beta / IFNB Protein
IFN-beta / IFNB Protein Price Inquiry ( Available Sizes )
- 200μg: Inquiring Price;
- ≥1mg Bulk: Inquiring Price
IFN-beta / IFNB Protein Product Information
| Synonym : |
IFNB1, IFB, IFF, IFNB, MGC96956 |
| Protein Construction: |
A DNA sequence encoding the human IFNβ ( NP_002167.1 ) ( Met 1 - Asn 187 ) was expressed and purified |
| Source: | Human |
| Expression Host: | CHO stable cells |
IFN-beta / IFNB Protein QC Testing
| Purity: | > 92 % as determined by SDS-PAGE | SDS-PAGE:![]() IFNB protein |
|
Bio-activity: |
Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV) The EC50 for this effect is typically 10 - 50 pg/mL |
|
| Endotoxin: | < 1.0 EU per μg of the protein as determined by the LAL method | |
| Stability: | Samples are stable for up to twelve months from date of receipt at -70℃ | |
| Predicted N terminal: | Met 22 | |
| Molecular Mass: |
The recombinant human IFNβ consists of 166 amino acids and has a predicted molecular mass of 20 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh IFNβis approximately 22 -24 kDa. |
|
| Formulation: | Lyophilized from sterile 20mM HEPES, 150mM NaCl, pH 7.2
|
IFN-beta / IFNB Protein Usage Guide
| Storage: | Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution: | A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information. |
IFN-beta / IFNB Protein Related Products & Topics
Related Areas:
Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IFN beta/IFNB
Immunology>>Cytokine & Receptor>>Interleukin & Receptor >>IL-10/Interferon Family>>IFN beta/IFNB
Proteins:
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| IFN beta/IFNB | Human | IFN beta/IFNB/Fc Protein, Recombinant![]() |
10704-H02H |
| IFN beta/IFNB | Human | IFN beta/IFNB Protein, Recombinant![]() |
10704-HNAC |
Antibodies:
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| Human IFN beta/IFNB |
WB, ELISA | Mouse Monoclonal Antibody | 10704-MM01 |
IFN-beta / IFNB Protein Description
Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. IFNs are produced by a wide variety of cells in response to the presence of dsRNA, a key indicator of viral infection via a pattern recognition receptor of the innate immune system Toll Like Receptor 3 (TLR 3), and in turn assists the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to lymphocytes, and inducing the resistance of host cells to viral infection. There are three major classes of IFNs according to the receptor type through which they signal, and the type I IFNs bind to a specific receptor complex known as the IFN-α receptor (IFNAR) consisting of IFNAR1 and IFNAR2 chains. The type I IFNs present in humans are IFN-α, IFN-β and IFN-ω and IFN-β is produced by fibroblast. In addition to the common antiviral activity, IFN-β also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. Furthermore, IFN-β might play a beneficial role in the development of a chronic progressive CNS inflammation.
References
- Morikawa K. et al., 1987, J Immunol. 139: 761-6.
- Sato K. et al., 2001, Eur J Immunol. 31: 3188-46.
- Takaoka A. et al., 2003, Nature. 424: 516-23.
- Improta T. et al., 1997, Cytokine. 9: 383-93.
- Teige I. et al., 2006, J Immunol. 177: 3542-53.
+86-400-890-9989







